New hope for drug-resistant lung cancer? early trial combines two targeted therapies
NCT ID NCT04001777
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug (APG-1252) combined with a standard targeted therapy (osimertinib) in people with a specific type of advanced lung cancer (EGFR-positive NSCLC) whose cancer has stopped responding to previous treatments. The main goals are to find the safest dose and check if the combination can shrink tumors. About 80 adults are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
-
Henan Provincial people's Hospital
Zhengzhou, Henan, China
-
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
-
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.